Literature DB >> 9827289

Clinical and laboratory spectrum of culture-proven human granulocytic ehrlichiosis: comparison with culture-negative cases.

H W Horowitz1, M E Aguero-Rosenfeld, D F McKenna, D Holmgren, T C Hsieh, S A Varde, S J Dumler, J M Wu, I Schwartz, Y Rikihisa, G P Wormser.   

Abstract

We describe the clinical and laboratory manifestations of human granulocytic ehrlichiosis (HGE) in eight patients for whom cultures were positive for the HGE agent and compare them with 15 patients for whom cultures were negative but who fulfilled a modified New York State Surveillance definition for HGE. Polymerase chain reaction analysis was positive in 8 (100%) of 8 culture-positive cases vs. 3 (20%) of 15 culture-negative cases (P < .001), morulae were detected in 7 (100%) of 7 culture-positive cases in which tests were performed vs. 0 of 15 culture-negative cases (P < .001), and a fourfold change in antibody titer was demonstrated in 6 (75%) of 8 culture-positive cases vs. 9 (69%) of 13 culture-negative cases (P = not significant). Patients for whom cultures were positive had higher mean oral temperatures +/- SD at presentation than did patients for whom cultures were negative (38.6 degrees C +/- 0.7 degree C vs. 37.2 degrees C +/- 0.8 degree C, respectively; P = .002). Other symptoms and signs were not significantly different between the two groups. Multivariate analysis revealed that the lymphocyte count at presentation was significantly lower in culture-positive cases than in culture-negative cases. Clinical response to treatment was similar in the two groups. Culture confirmation of HGE is the gold standard for defining the sensitivity and specificity of other diagnostic tests presently being developed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827289     DOI: 10.1086/515000

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Serology of culture-confirmed cases of human granulocytic ehrlichiosis.

Authors:  M E Aguero-Rosenfeld; F Kalantarpour; M Baluch; H W Horowitz; D F McKenna; J T Raffalli; T c Hsieh; J Wu; J S Dumler; G P Wormser
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

3.  Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epank1 genes of Ehrlichia phagocytophila-group ehrlichiae.

Authors:  J J Walls; P Caturegli; J S Bakken; K M Asanovich; J S Dumler
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Expansion of the Midwestern focus for human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin.

Authors:  Steven D Lovrich; Dean A Jobe; Todd J Kowalski; Seema M Policepatil; Steven M Callister
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

5.  Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test.

Authors:  J J Walls; M Aguero-Rosenfeld; J S Bakken; J L Goodman; D Hossain; R C Johnson; J S Dumler
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Outcome of diagnostic tests using samples from patients with culture-proven human monocytic ehrlichiosis: implications for surveillance.

Authors:  J E Childs; J W Sumner; W L Nicholson; R F Massung; S M Standaert; C D Paddock
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

7.  Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia.

Authors:  S Lotric-Furlan; T Avsic-Zupanc; M Petrovec; W L Nicholson; J W Sumner; J E Childs; F Strle
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

8.  Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44.

Authors:  H Y Kim; Y Rikihisa
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

9.  Isolation and propagation of the Ap-Variant 1 strain of Anaplasma phagocytophilum in a tick cell line.

Authors:  Robert F Massung; Michael L Levin; Ulrike G Munderloh; David J Silverman; Meghan J Lynch; Jariyanart K Gaywee; Timothy J Kurtti
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

10.  Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting.

Authors:  Juan P Olano; Wayne Hogrefe; Brent Seaton; David H Walker
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.